Enzyvant, a biopharmaceutical company focused on developing therapies for people with rare diseases, announced yesterday that it has named George O Elston as its chief financial officer and head of corporate development.

Elston is a veteran biopharmaceutical executive with more than 25 years' experience leading global business and financial operations for start-up, private and public companies. He most recently served as president and chief executive officer of 2X Oncology Inc and was earlier the chief financial officer at Juniper Pharmaceuticals Inc. Currently he is a trustee and audit committee chairman for the Deutsche Bank AG - DBX Trust.

Alvin Shih, MD, chief executive officer of Enzyvant, said, 'George has a tremendous background ideally suited to Enzyvant. His broad-based experience and excellent track record speak to his ability to bring immense value as we look forward to achieving our near-term milestones, including completion of the rolling RVT-802 BLA filing and initiation of the RVT-801 clinical study.'